LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals today announced positive top-line results from a Phase 1/2 randomized, double-blind, placebo-controlled clinical trial of the Company’s lead ...
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals today presented positive preclinical results supporting the Company’s lead clinical-stage drug candidate in glaucoma, INO-8875. INO-8875 is a ...
BEVERLY, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation announced today that the United States Patent and Trademark Office has issued two new patents covering the Company's two lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results